Med BioGene Gets Additional Investment from SEP Capital | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene today said that it has signed an agreement with SEP Capital to sell nearly C$500,000 (US$434,000) in units to the investment firm in a private placement.

The deal comes on the heels of Med BioGene raising C$1.6 million through a private placement last month of 20 million units in two tranches. The Vancouver, BC-based molecular diagnostics firm said that SEP will invest all of its available cash reserves — C$475,979 as of Dec. 31, 2008 — in the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.